Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(00)01331-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Roxadustat-Induced Central Hypothyroidism Masked by Uremia at the Initiation of Hemodialysis: A Case Report.
Cureus
December 2024
Nephrology, Yokohama Municipal Citizen's Hospital, Yokohama, JPN.
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a novel class of orally administered medications for renal anemia in patients with end-stage renal disease (ESRD). Roxadustat, a HIF-PHI, has a structure similar to that of triiodothyronine and may work as an agonist for thyroid hormone receptor-beta in the pituitary gland and/or hypothalamus. Therefore, roxadustat may cause central hypothyroidism due to suppressing thyroid-stimulating hormone (TSH) release in the pituitary gland and/or thyrotropin-releasing hormone release in the hypothalamus.
View Article and Find Full Text PDFEffect of a Low-Molecular-Weight Allosteric Agonist of the Thyroid-Stimulating Hormone Receptor on Basal and Thyroliberin-Stimulated Activity of Thyroid System in Diabetic Rats.
Int J Mol Sci
January 2025
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg 194223, Russia.
The approaches to correct thyroid deficiency include replacement therapy with thyroid hormones (THs), but such therapy causes a number of side effects. A possible alternative is thyroid-stimulating hormone (TSH) receptor activators, including allosteric agonists. The aim of this work was to study the effect of ethyl-2-(4-(4-(5-amino-6-(-butylcarbamoyl)-2-(methylthio)thieno[2,3-d]pyrimidin-4-yl)phenyl)--1,2,3-triazol-1-yl) acetate (TPY3m), a TSH receptor allosteric agonist developed by us, on basal and thyroliberin (TRH)-stimulated TH levels and the hypothalamic-pituitary-thyroid (HPT) axis in male rats with high-fat diet/low-dose streptozotocin-induced type 2 diabetes mellitus (T2DM).
View Article and Find Full Text PDFTreatment of Primary Hypothyroidism by Slow-Release Liothyronine Monotherapy.
Endocr Metab Immune Disord Drug Targets
January 2025
Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Combination therapy with levothyroxine (L-T4) and slow-release T3 (SRT3) in the treatment of hypothyroidism results in a normal triiodothyronine/thyroxine (T3/T4) ratio above that of L-T4 monotherapy. No clinical study has been reported with SRT3 monotherapy for hypothyroidism.
Methods: This study was conducted in two parts.
Turner Syndrome and the Thyroid Function-A Systematic and Critical Review.
Int J Mol Sci
December 2024
Department of General and Transplant Surgery, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
Turner syndrome (TS) is associated with thyroid disorders. Since the rate of thyroid disease among patients with this syndrome is significantly higher as compared to the general population, it seems vital to explore this particular area. This systematic and critical review was performed to evaluate thyroid function and autoimmunity in patients with Turner syndrome.
View Article and Find Full Text PDFThyrotoxic Periodic Paralysis: A Unique Case Highlighting the Diagnostic Challenges and Management.
Cureus
November 2024
Internal Medicine Department, Saint Joseph Hospital, Jerusalem, PSE.
Thyrotoxic periodic paralysis (TPP) is a rare complication primarily associated with thyrotoxicosis, particularly in individuals with Graves' disease. While more common in males aged 20 to 40, it can occur across all ethnic backgrounds. It is the most common type of acquired periodic paralysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!